Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood-brain barrier permeability for escitalopram and ABCB1 genotypes: effects on sleep and motor learning
2006-001491-21Phase 3Active
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of escitalopram, sponsored by Max Planck Institute of Psychiatry. Primary endpoints: Primary: Brain and serum concentrations of escitalopram and Primary: Change in sleep EEG variables. Started Jun 2006; status: active.
02
Drugs
escitalopram
Beyond the preview
Go deeper on 2006-001491-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001491-21.